ClinicalTrials.gg
RecruitingNCT06571500GHRB-BUpdated May 11, 2026

Growth Hormone Resistance of Beta-cells in People With a Family History of Type 2 Diabetes

An observational study in Healthy and Obesity, sponsored by University of Missouri-Columbia. Recruiting at 1 site in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by University of Missouri-Columbia · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Obesity by University of Missouri-Columbia — 8 open to participants now, 9 under way, none of them phase 3. Obesity · University of Missouri-Columbia.

Started
2025
with 3 others
Observational
5 of 34
4 open now
Registered
26th of 34
by date

Among the 34 studies in Obesity by University of Missouri-Columbia, this one is one of 4 that started in 2025, is one of 5 observational ones, and was the 26th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 34 studies in Obesity by University of Missouri-Columbia are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Obesity by University of Missouri-Columbia, or all of them as a file.
02

Study summary

The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a family history of type 2 diabetes at the University of Missouri. Our aim is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.

03

Conditions studied

  • Healthy
  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of obese men and women ages 18-45 with and without a first degree relative with type 2 diabetes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 59 years old
  • ≥30.0 kg/m2 and \<45.0 kg/m2

Additional, group-specific inclusion criteria:

  • Family history of type 2 diabetes: first degree relative with type 2 diabetes
  • Control group: no family history of type 2 diabetes

Exclusion criteria

Exclusion Criteria:

  • Pregnant, planning to become pregnant during the study, or breastfeeding
  • Current diagnosis or history of type 1 or type 2 diabetes
  • Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
  • History of bariatric surgery
  • Known, uncontrolled hypothyroidism
  • History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
  • Current cancer or cancer that has been in remission less than 5 years
  • First degree relative with type 1 diabetes diagnosis
  • Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
  • Alcohol use disorder, use of controlled substances, or smoking >2 cigarettes per day
  • Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration
  • Mentally disabled persons, prisoners, and persons with inability to grant voluntary
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Men and women with a family history of type 2 diabetes
  • Men and women without a family history of type 2 diabetes
06

What researchers measure

Primary outcomes

  1. Beta-cell function

    Insulin secretion rate in relationship to plasma glucose

    Time frame: before and 7 days after rhGH administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data will be available upon reasonable request

Time frame: 5 years after completion of the study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Sep 2028, 37 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 37 months is close to that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2024
First posted
Aug 26, 2024
StartActual
Jul 15, 2025
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2030
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06571500
Responsible party
Bettina Mittendorfer (Senior Associate Dean for Research; Professor, Medicine & Nutrition; NextGen Director of Clinical and Translational Sciences Unit, University of Missouri-Columbia) — Principal investigator
First posted
Aug 26, 2024
Start date
Jul 15, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
May 11, 2026

Study contacts

Amanda Heider
Contact
ahmc4@health.missouri.edu
573-884-6852
Vasavi Shabrish, PhD
Contact
v.shabrish@missouri.edu
Bettina Mittendorfer, PhD
principal investigator · University of Missouri-Columbia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion